Galderma @ AAD 2024: new data demonstrate the long-term efficacy of nemolizumab in prurigo nodularis and its durability in atopic dermatitis Press release
Galderma announces record 2023 net sales of over 4 B USD and significant core EBITDA margin expansion Press release
Galderma to showcase latest updates from its broad, innovative and leading dermatology portfolio at the 2024 American Academy of Dermatology annual meeting Press release
Galderma announces regulatory filing acceptance for nemolizumab in prurigo nodularis and atopic dermatitis in the U.S. and EU Press release
Galderma launches ‘NEXT’, a ground-breaking trend report that unveils the future of aesthetics Press release
Galderma celebrates 25 years of excellence in biostimulation with Sculptra® at the 2024 IMCAS Press release
IMCAS 2024: Galderma to present latest updates from its unparalleled aesthetics portfolio reinforcing its leadership position Press release
Galderma announces regulatory approval for Restylane® SHAYPE™, a new hyaluronic acid injectable designed for augmenting the chin region Press release
TOXINS 2024: Galderma’s phase III RelabotulinumtoxinA results demonstrate positive efficacy and long duration of effect when treating frown lines and crow’s feet simultaneously Press release
